476 related articles for article (PubMed ID: 21972097)
21. Myelination- and immune-mediated MR-based brain network correlates.
Cerina M; Muthuraman M; Gallus M; Koirala N; Dik A; Wachsmuth L; Hundehege P; Schiffler P; Tenberge JG; Fleischer V; Gonzalez-Escamilla G; Narayanan V; Krämer J; Faber C; Budde T; Groppa S; Meuth SG
J Neuroinflammation; 2020 Jun; 17(1):186. PubMed ID: 32532336
[TBL] [Abstract][Full Text] [Related]
22. Leukemia inhibitory factor signaling modulates both central nervous system demyelination and myelin repair.
Marriott MP; Emery B; Cate HS; Binder MD; Kemper D; Wu Q; Kolbe S; Gordon IR; Wang H; Egan G; Murray S; Butzkueven H; Kilpatrick TJ
Glia; 2008 Apr; 56(6):686-98. PubMed ID: 18293407
[TBL] [Abstract][Full Text] [Related]
23. Pathological changes in mice with long term cuprizone administration.
Nomura T; Bando Y; Nakazawa H; Kanemoto S; Yoshida S
Neurochem Int; 2019 Jun; 126():229-238. PubMed ID: 30940543
[TBL] [Abstract][Full Text] [Related]
24. A new model of cuprizone-mediated demyelination/remyelination.
Sachs HH; Bercury KK; Popescu DC; Narayanan SP; Macklin WB
ASN Neuro; 2014; 6(5):. PubMed ID: 25290063
[TBL] [Abstract][Full Text] [Related]
25. Quantitative temporal changes in DTI values coupled with histological properties in cuprizone-induced demyelination and remyelination.
Yano R; Hata J; Abe Y; Seki F; Yoshida K; Komaki Y; Okano H; Tanaka KF
Neurochem Int; 2018 Oct; 119():151-158. PubMed ID: 29030079
[TBL] [Abstract][Full Text] [Related]
26. Effects of acute and repeated exposure to lipopolysaccharide on cytokine and corticosterone production during remyelination.
Urbach-Ross D; Kusnecov AW
Brain Behav Immun; 2007 Oct; 21(7):962-74. PubMed ID: 17490854
[TBL] [Abstract][Full Text] [Related]
27. Chronic toxic demyelination in the central nervous system leads to axonal damage despite remyelination.
Lindner M; Fokuhl J; Linsmeier F; Trebst C; Stangel M
Neurosci Lett; 2009 Apr; 453(2):120-5. PubMed ID: 19356606
[TBL] [Abstract][Full Text] [Related]
28. CXCR2-positive neutrophils are essential for cuprizone-induced demyelination: relevance to multiple sclerosis.
Liu L; Belkadi A; Darnall L; Hu T; Drescher C; Cotleur AC; Padovani-Claudio D; He T; Choi K; Lane TE; Miller RH; Ransohoff RM
Nat Neurosci; 2010 Mar; 13(3):319-26. PubMed ID: 20154684
[TBL] [Abstract][Full Text] [Related]
29. Targeting demyelination via α-secretases promoting sAPPα release to enhance remyelination in central nervous system.
Llufriu-Dabén G; Carrete A; Chierto E; Mailleux J; Camand E; Simon A; Vanmierlo T; Rose C; Allinquant B; Hendriks JJA; Massaad C; Meffre D; Jafarian-Tehrani M
Neurobiol Dis; 2018 Jan; 109(Pt A):11-24. PubMed ID: 28923597
[TBL] [Abstract][Full Text] [Related]
30. Region-specific susceptibilities to cuprizone-induced lesions in the mouse forebrain: Implications for the pathophysiology of schizophrenia.
Yang HJ; Wang H; Zhang Y; Xiao L; Clough RW; Browning R; Li XM; Xu H
Brain Res; 2009 May; 1270():121-30. PubMed ID: 19306847
[TBL] [Abstract][Full Text] [Related]
31. Clemastine rescues behavioral changes and enhances remyelination in the cuprizone mouse model of demyelination.
Li Z; He Y; Fan S; Sun B
Neurosci Bull; 2015 Oct; 31(5):617-25. PubMed ID: 26253956
[TBL] [Abstract][Full Text] [Related]
32. Demyelination of the hippocampus is prominent in the cuprizone model.
Koutsoudaki PN; Skripuletz T; Gudi V; Moharregh-Khiabani D; Hildebrandt H; Trebst C; Stangel M
Neurosci Lett; 2009 Feb; 451(1):83-8. PubMed ID: 19084049
[TBL] [Abstract][Full Text] [Related]
33. Cortical demyelination is prominent in the murine cuprizone model and is strain-dependent.
Skripuletz T; Lindner M; Kotsiari A; Garde N; Fokuhl J; Linsmeier F; Trebst C; Stangel M
Am J Pathol; 2008 Apr; 172(4):1053-61. PubMed ID: 18349131
[TBL] [Abstract][Full Text] [Related]
34. The neurotoxicant, cuprizone, as a model to study demyelination and remyelination in the central nervous system.
Matsushima GK; Morell P
Brain Pathol; 2001 Jan; 11(1):107-16. PubMed ID: 11145196
[TBL] [Abstract][Full Text] [Related]
35. Cerebellar cortical demyelination in the murine cuprizone model.
Skripuletz T; Bussmann JH; Gudi V; Koutsoudaki PN; Pul R; Moharregh-Khiabani D; Lindner M; Stangel M
Brain Pathol; 2010 Mar; 20(2):301-12. PubMed ID: 19371354
[TBL] [Abstract][Full Text] [Related]
36. Evaluation strategy to determine reliable demyelination in the cuprizone model.
Chrzanowski U; Schmitz C; Horn-Bochtler A; Nack A; Kipp M
Metab Brain Dis; 2019 Apr; 34(2):681-685. PubMed ID: 30607821
[TBL] [Abstract][Full Text] [Related]
37. Protective and therapeutic role of 2-carba-cyclic phosphatidic acid in demyelinating disease.
Yamamoto S; Yamashina K; Ishikawa M; Gotoh M; Yagishita S; Iwasa K; Maruyama K; Murakami-Murofushi K; Yoshikawa K
J Neuroinflammation; 2017 Jul; 14(1):142. PubMed ID: 28732510
[TBL] [Abstract][Full Text] [Related]
38. Spatio-Temporal Patterns of Demyelination and Remyelination in the Cuprizone Mouse Model.
Tagge I; O'Connor A; Chaudhary P; Pollaro J; Berlow Y; Chalupsky M; Bourdette D; Woltjer R; Johnson M; Rooney W
PLoS One; 2016; 11(4):e0152480. PubMed ID: 27054832
[TBL] [Abstract][Full Text] [Related]
39. Neuroprotective effect of linagliptin against cuprizone-induced demyelination and behavioural dysfunction in mice: A pivotal role of AMPK/SIRT1 and JAK2/STAT3/NF-κB signalling pathway modulation.
Elbaz EM; Senousy MA; El-Tanbouly DM; Sayed RH
Toxicol Appl Pharmacol; 2018 Aug; 352():153-161. PubMed ID: 29864483
[TBL] [Abstract][Full Text] [Related]
40. Effect of the CSF1R inhibitor PLX3397 on remyelination of corpus callosum in a cuprizone-induced demyelination mouse model.
Tahmasebi F; Pasbakhsh P; Mortezaee K; Madadi S; Barati S; Kashani IR
J Cell Biochem; 2019 Jun; 120(6):10576-10586. PubMed ID: 30628737
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
